Precigen Past Earnings Performance
Past criteria checks 0/6
Precigen has been growing earnings at an average annual rate of 25.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 50.3% per year.
Key information
25.5%
Earnings growth rate
38.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -50.3% |
| Return on equity | -313.6% |
| Net Margin | -3,084.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Precigen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4 | -135 | 40 | 0 |
| 31 Mar 24 | 5 | -97 | 39 | 0 |
| 31 Dec 23 | 6 | -96 | 40 | 0 |
| 30 Sep 23 | 7 | -85 | 42 | 0 |
| 30 Jun 23 | 22 | -73 | 43 | 0 |
| 31 Mar 23 | 23 | -79 | 46 | 0 |
| 31 Dec 22 | 27 | -80 | 48 | 0 |
| 30 Sep 22 | 29 | -84 | 48 | 0 |
| 30 Jun 22 | 15 | -103 | 49 | 0 |
| 31 Mar 22 | 16 | -108 | 51 | 0 |
| 31 Dec 21 | 14 | -111 | 52 | 0 |
| 30 Sep 21 | 30 | -124 | 71 | 0 |
| 30 Jun 21 | 50 | -125 | 82 | 0 |
| 31 Mar 21 | 77 | -110 | 85 | 0 |
| 31 Dec 20 | 32 | -104 | 73 | 0 |
| 30 Sep 20 | 101 | -100 | 88 | 0 |
| 30 Jun 20 | 96 | -122 | 88 | 0 |
| 31 Mar 20 | 98 | -138 | 89 | 0 |
| 31 Dec 19 | 91 | -169 | 99 | 0 |
| 30 Sep 19 | 108 | -373 | 85 | 0 |
| 30 Jun 19 | 122 | -381 | 102 | 0 |
| 31 Mar 19 | 134 | -414 | 117 | 0 |
| 31 Dec 18 | 151 | -375 | 125 | 0 |
| 30 Sep 18 | 194 | -196 | 148 | 0 |
| 30 Jun 18 | 208 | -179 | 148 | 0 |
| 31 Mar 18 | 217 | -132 | 153 | 0 |
| 31 Dec 17 | 219 | -71 | 130 | 0 |
| 30 Sep 17 | 200 | -134 | 148 | 0 |
| 30 Jun 17 | 203 | -123 | 143 | 0 |
| 31 Mar 17 | 201 | -154 | 134 | 0 |
| 31 Dec 16 | 191 | -187 | 138 | 0 |
| 30 Sep 16 | 186 | -175 | 137 | 0 |
| 30 Jun 16 | 191 | -184 | 125 | 0 |
| 31 Mar 16 | 183 | -176 | 118 | 0 |
| 31 Dec 15 | 174 | -84 | 107 | 0 |
| 30 Sep 15 | 163 | -33 | 92 | 0 |
| 30 Jun 15 | 131 | -47 | 85 | 0 |
| 31 Mar 15 | 98 | -59 | 76 | 0 |
| 31 Dec 14 | 72 | -82 | 63 | 0 |
| 30 Sep 14 | 48 | -113 | 53 | 0 |
| 30 Jun 14 | 33 | -52 | 46 | 0 |
| 31 Mar 14 | 28 | -11 | 39 | 0 |
| 31 Dec 13 | 24 | -57 | 33 | 0 |
Quality Earnings: I5X is currently unprofitable.
Growing Profit Margin: I5X is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: I5X is unprofitable, but has reduced losses over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare I5X's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: I5X is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).
Return on Equity
High ROE: I5X has a negative Return on Equity (-313.6%), as it is currently unprofitable.